Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Chemotherapy. Hormone. Immunotherapy. University Medical Center Groningen, Groningen, Netherlands



Survival: 27.0 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
Hormone
Immunotherapy
   
Drugs:
Country: Netherlands
   
City/State/Province: Groningen
   
Hospital: University Medical Center Groningen
   
Journal: Link
   
Date: 7/2011

Description:
Patients:
This study involved 20 patients with T-cell lymphoma. The median patient age was 50 years and 11 were males.

Treatment:
Patients were treated with the chemotherapy agents cyclophosphamide, doxorubicin, and vincristine, the hormone prednisone, and the immune therapy agent alemtuzumab (antibody against CD52 that directs the immune system to attack cancer cells).

Toxicities:
Treatment-related deaths due to infection and pneumonia were reported.

Results:
The median overall survival was 27 months.

Support:
This study was partially supported by Bayer Schering Pharma (makers of alemtuzumab) and Genzyme.

Correspondence: Dr. H. C. Kluin-Nelemans; email: j.c.kluin@int.umcg.nl

E-mail to a Friend Email Physician More Information